Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



U.K. Rightmove House Price Index YoY (Dec)A:--
F: --
P: --
China, Mainland Industrial Output YoY (YTD) (Nov)A:--
F: --
P: --
China, Mainland Urban Area Unemployment Rate (Nov)A:--
F: --
P: --
Saudi Arabia CPI YoY (Nov)A:--
F: --
P: --
Euro Zone Industrial Output YoY (Oct)A:--
F: --
P: --
Euro Zone Industrial Output MoM (Oct)A:--
F: --
P: --
Canada Existing Home Sales MoM (Nov)A:--
F: --
P: --
Canada National Economic Confidence IndexA:--
F: --
P: --
Canada New Housing Starts (Nov)A:--
F: --
U.S. NY Fed Manufacturing Employment Index (Dec)A:--
F: --
P: --
U.S. NY Fed Manufacturing Index (Dec)A:--
F: --
P: --
Canada Core CPI YoY (Nov)A:--
F: --
P: --
Canada Manufacturing Unfilled Orders MoM (Oct)A:--
F: --
P: --
U.S. NY Fed Manufacturing Prices Received Index (Dec)A:--
F: --
P: --
U.S. NY Fed Manufacturing New Orders Index (Dec)A:--
F: --
P: --
Canada Manufacturing New Orders MoM (Oct)A:--
F: --
P: --
Canada Core CPI MoM (Nov)A:--
F: --
P: --
Canada Trimmed CPI YoY (SA) (Nov)A:--
F: --
P: --
Canada Manufacturing Inventory MoM (Oct)A:--
F: --
P: --
Canada CPI YoY (Nov)A:--
F: --
P: --
Canada CPI MoM (Nov)A:--
F: --
P: --
Canada CPI YoY (SA) (Nov)A:--
F: --
P: --
Canada Core CPI MoM (SA) (Nov)A:--
F: --
P: --
Canada CPI MoM (SA) (Nov)A:--
F: --
P: --
Federal Reserve Board Governor Milan delivered a speech
U.S. NAHB Housing Market Index (Dec)A:--
F: --
P: --
Australia Composite PMI Prelim (Dec)A:--
F: --
P: --
Australia Services PMI Prelim (Dec)A:--
F: --
P: --
Australia Manufacturing PMI Prelim (Dec)A:--
F: --
P: --
Japan Manufacturing PMI Prelim (SA) (Dec)A:--
F: --
P: --
U.K. 3-Month ILO Employment Change (Oct)--
F: --
P: --
U.K. Unemployment Claimant Count (Nov)--
F: --
P: --
U.K. Unemployment Rate (Nov)--
F: --
P: --
U.K. 3-Month ILO Unemployment Rate (Oct)--
F: --
P: --
U.K. Average Weekly Earnings (3-Month Average, Including Bonuses) YoY (Oct)--
F: --
P: --
U.K. Average Weekly Earnings (3-Month Average, Excluding Bonuses) YoY (Oct)--
F: --
P: --
France Services PMI Prelim (Dec)--
F: --
P: --
France Composite PMI Prelim (SA) (Dec)--
F: --
P: --
France Manufacturing PMI Prelim (Dec)--
F: --
P: --
Germany Services PMI Prelim (SA) (Dec)--
F: --
P: --
Germany Manufacturing PMI Prelim (SA) (Dec)--
F: --
P: --
Germany Composite PMI Prelim (SA) (Dec)--
F: --
P: --
Euro Zone Composite PMI Prelim (SA) (Dec)--
F: --
P: --
Euro Zone Services PMI Prelim (SA) (Dec)--
F: --
P: --
Euro Zone Manufacturing PMI Prelim (SA) (Dec)--
F: --
P: --
U.K. Services PMI Prelim (Dec)--
F: --
P: --
U.K. Manufacturing PMI Prelim (Dec)--
F: --
P: --
U.K. Composite PMI Prelim (Dec)--
F: --
P: --
Euro Zone ZEW Economic Sentiment Index (Dec)--
F: --
P: --
Germany ZEW Current Conditions Index (Dec)--
F: --
P: --
Germany ZEW Economic Sentiment Index (Dec)--
F: --
P: --
Euro Zone Trade Balance (Not SA) (Oct)--
F: --
P: --
Euro Zone ZEW Current Conditions Index (Dec)--
F: --
P: --
Euro Zone Trade Balance (SA) (Oct)--
F: --
P: --
Euro Zone Total Reserve Assets (Nov)--
F: --
P: --
U.K. Inflation Rate Expectations--
F: --
P: --
U.S. Unemployment Rate (SA) (Nov)--
F: --
P: --
U.S. Nonfarm Payrolls (SA) (Nov)--
F: --
P: --
U.S. Retail Sales MoM (Excl. Gas Stations & Vehicle Dealers) (SA) (Oct)--
F: --
P: --
U.S. Retail Sales MoM (Excl. Automobile) (SA) (Oct)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
A major transformation is underway, with a strategic exit from cell therapy and a focus on redeploying €3 billion in cash into de-risked immunology and oncology assets. Key catalysts ahead include the cell therapy wind down, TIC2 phase 2 data, and new business development deals.
Based on Galapagos NV [GLPG] Jefferies London Healthcare Conference 2025 Audio Transcript — Nov. 19 2025
(19:15 GMT) Galapagos Price Target Raised to $32.00/Share From $28.00 by RBC Capital
Announced wind down of the cell therapy business after failed sale, incurring major impairments and restructuring costs. Focus shifts to business development, leveraging a strong cash position and Gilead partnership to pursue de-risked opportunities in oncology and immunology.
Based on Galapagos NV [GLPG] Q3 2025 Audio Transcript — Nov. 6 2025
Strategic review led to the decision to wind down the cell therapy business, resulting in a €204.8 million impairment and a net loss of €461.3 million for the first nine months of 2025. Cash and financial investments remain robust at €3.05 billion.
Original document: Galapagos NV [GLPG] SEC 6-K Current Report — Nov. 6 2025
Announced a major transformation with the wind down of the cell therapy business, significant impairment charges, and a sharpened focus on business development. Maintains a strong cash position and expects to be cash flow neutral to positive by YE26, with topline clinical results for GLPG3667 anticipated in early 2026.
Original document: Galapagos NV [GLPG] Slides Release — Nov. 6 2025
Strategic review led to the planned wind down of the cell therapy business, resulting in a €204.8 million impairment and a significant operating loss. The company maintains a strong cash position and will focus on business development in immunology and oncology, with a leaner organization and new leadership.
Original document: Galapagos NV [GLPG] Interim report — Nov. 6 2025
(14:27 GMT) Galapagos Price Target Raised to $28.00/Share From $27.00 by RBC Capital
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up